Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL-II: 3-DAA Regimen +/- Ribavirin in HCV GT1b
NCT01674725Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2012
- Primary completion
- Jan 2014
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of paritaprevir, ombitasvir, dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Aug 2012; status: completed.
02
Drugs
paritaprevirombitasvirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01674725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01674725.